Vaccine Candidates for RSV Ward Off Severe Illness in Older Adults

October 27, 2022

(MedPage Today) – Prefusion F protein vaccine candidates for respiratory syncytial virus (RSV) proved safe in adults 60 and up while demonstrating an ability to thwart lower respiratory tract illness, including severe cases, a pair of large phase III trials showed. (Read More)